Fresno Has California's Highest Adult Obesity Rate. The GLP-1 Conversation Here Deserves Better Than an Ad.

Fresno County has the highest adult obesity prevalence of any county in California.

Not among the highest. The highest. In the CDC’s PLACES county estimates, built on 2023 BRFSS data, 37.7% of Fresno County adults have obesity. Across all 58 California counties the population-weighted figure is 27.8%. San Francisco County is 17.2%. Our neighbors sit just behind us — Madera 36.5%, Stanislaus 36.4%, Kern 36.0%, Tulare 35.0%. The Central Valley is the center of this map, and Fresno is the center of the Valley.

The same dataset puts diagnosed diabetes among Fresno adults at 12.7%, high blood pressure at 31.7%, and adults reporting no leisure-time physical activity at 30.9%.

So when a national advertising category arrives here — and GLP-1 weight-loss medication has arrived here, loudly — it lands on a population with more at stake than the average American city. That is a reason for the conversation to be more careful, not less.

This is the version of that conversation we would have with a patient sitting across from us.

Six brand names. Two molecules. One of them is now a cardiovascular drug.

Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management; Novo Nordisk also now markets an oral semaglutide tablet under the Wegovy name. Tirzepatide is sold as Mounjaro for diabetes and as Zepbound for weight management, and it acts on two receptors — GIP and GLP-1 — rather than one.

Ozempic became the household word, so people search for the name they have heard rather than the drug they would actually be prescribed. That confusion is not harmless. It is the opening that low-quality sellers use.

One development deserves more attention than it gets. In the SELECT trial, 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or greater, but without diabetes, were randomized to semaglutide 2.4 mg or placebo. Over a mean 39.8 months of follow-up, a major adverse cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group, a hazard ratio of 0.80 (95% CI, 0.72 to 0.90). That result is now reflected in Wegovy’s FDA label.

The relevant point for a patient is not the effect size. It is the category change. This is a cardiovascular medication with a boxed warning, prescribed against a risk profile. It is not a cosmetic product, and it should not be bought like one.

What the trials measured

STEP 1 (NEJM, 2021) randomized 1,961 adults with a BMI of 30 or greater — or 27 or greater with a weight-related condition — and without diabetes, to 68 weeks of once-weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo. At least 5% lost by 86.4% versus 31.5%; at least 10% by 69.1% versus 12.0%; at least 15% by 50.5% versus 4.9%. In absolute terms, −15.3 kg versus −2.6 kg.

SURMOUNT-1 (NEJM, 2022) randomized 2,539 adults, excluding diabetes, to 72 weeks of tirzepatide at 5, 10 or 15 mg, or placebo. Mean weight change was −15.0%, −19.5% and −20.9% respectively, versus −3.1%. In the 15 mg group, 57% lost at least 20% of body weight, against 3% on placebo.

SURMOUNT-5 (NEJM, 2025) is the one that answers the question people actually ask. It put the two molecules head to head: 751 adults with obesity and without diabetes, open-label, each randomized to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide. Waist circumference fell 18.4 cm versus 13.0 cm.

Both work. In a direct comparison, tirzepatide worked better on average.

Averages describe populations. They do not describe a person.

A trial mean is a summary of hundreds of different responses. Tolerability, cost, coverage, supply, comorbidities, interactions and prior history all move the decision for an individual, and none of them appear in a headline number.

Real-world data make the gap concrete. In a retrospective analysis of 20,998 US adults without type 2 diabetes who started tirzepatide, drawn from the Optum Market Clarity database, six-month persistence was 55.4% — nearly half were no longer on the medication. By the sixth prescription fill, 74.2% were still on a dose below 10 mg, meaning real-world escalation is markedly slower than the trial protocols. Among those who did persist six months with recorded weights, mean reduction was 11.9%. That study was conducted and funded by Eli Lilly, which should be weighed, but the persistence finding matches the broader pattern.

The honest reading: the trials show what these drugs can do under close supervision, tight titration and free medication. What they do in ordinary life depends heavily on whether anyone is supervising.

The muscle question is real, and it is not being discussed enough

In a DXA substudy of SURMOUNT-1, 160 participants had body composition measured at baseline and week 72. With tirzepatide, body weight fell 21.3%, fat mass 33.9% and lean mass 10.9%. About 75% of the weight lost was fat and about 25% was lean mass — and that proportion was essentially the same in the placebo group, and stable across sex, age and the size of the weight loss.

A 2026 systematic review in Annals of Internal Medicine went wider: 35 randomized trials reporting body composition. The median proportion of total weight loss attributable to muscle-based measures was 28.3% (IQR 15.9% to 39.9%), and about two-thirds of the incretin interventions exceeded the prespecified 25% benchmark. The reviewers also noted that no included study reported objective physical function outcomes — nobody measured whether patients got weaker.

Two things follow, and they point in opposite directions, so both belong in the same paragraph. First, this is not unique to drugs: in the same review, nearly half of the non-pharmacologic interventions that produced weight loss also exceeded their benchmark. Losing weight costs lean tissue by almost any method. Second, that is not a reason to ignore it. It is a reason that adequate protein intake and resistance training are part of the prescription rather than an optional lifestyle upsell, and a reason to measure rather than assume.

Stopping is where most of these stories go wrong

The STEP 1 trial extension followed 327 participants for a year after treatment and lifestyle intervention were withdrawn at week 68. Mean weight loss on semaglutide had been 17.3%. One year off the drug, participants had regained 11.6 of those 17.3 percentage points — about two-thirds — leaving a net 5.6% below baseline. Improvements in cardiometabolic measures reverted toward baseline alongside the weight.

This is the single most important fact in the category and the one least likely to appear in an ad. Obesity behaves as a chronic condition. These medications treat it while they are being taken. A plan that does not answer the question “what happens in year three” is not a plan.

Who should not take these, and what an actual screen looks like

Both semaglutide and tirzepatide carry an FDA boxed warning for thyroid C-cell tumors, based on dose- and duration-dependent tumors in rodents; human relevance is undetermined. Both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a serious hypersensitivity reaction to the drug. The labels also note that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection.

Beyond the contraindications, a competent evaluation covers pancreatitis history, gallbladder disease, severe gastrointestinal disease and gastroparesis, diabetic retinopathy, kidney function, pregnancy and pregnancy planning, and the complete current medication list. Because these drugs delay gastric emptying, patients also need to be told to inform their surgeon and anesthesiologist before any procedure requiring sedation — retained gastric contents are a recognized aspiration risk and there are now perioperative guidelines addressing it.

Gastrointestinal side effects are the most common adverse events in every trial, are mostly mild to moderate, and cluster during dose escalation. In STEP 1, 4.5% of the semaglutide group discontinued because of gastrointestinal events, versus 0.8% on placebo. In SURMOUNT-1, adverse events caused discontinuation in 4.3% to 7.1% across tirzepatide doses versus 2.6% on placebo. In SELECT, where exposure ran a mean of 34 months, permanent discontinuation for adverse events reached 16.6% versus 8.2%. Longer exposure, more discontinuation. Titration pace is a clinical decision, not a customer preference.

A prescriber who does not ask about any of this is not screening you. They are processing you.

What it costs in 2026

Coverage remains inconsistent. Many commercial plans exclude anti-obesity medication outright, so a large share of patients are paying cash. As listed by the manufacturers as of September 2026:

• Zepbound (tirzepatide), self-pay through LillyDirect: $299/month at 2.5 mg, $399/month at 5 mg, and $449/month at 7.5 mg and above — the higher-dose price conditional on completing each refill within 45 days of the previous one.

• Wegovy (semaglutide) pens through NovoCare Pharmacy: $349/month at standard doses, with a $199/month introductory price for the first two fills for new patients, and $399/month for the 7.2 mg HD pen.

• Wegovy oral tablets: $149/month at 1.5 mg, $199/month at 4 mg, and $299/month at 9 mg and 25 mg.

These programs are self-pay only, and the prices have been revised more than once. Confirm current terms before you budget around them.

Compounded GLP-1s are a different product, and the safety data show it

Most of the aggressively priced offers online are not these drugs. They are compounded semaglutide or tirzepatide — not FDA-approved, not subject to the same manufacturing and testing requirements.

That market existed largely because both drugs were on the FDA shortage list, which opens a legal pathway for compounding. Those shortages have been resolved. FDA’s enforcement discretion for 503B outsourcing facilities compounding tirzepatide ended March 19, 2025; for 503A pharmacies and physicians compounding semaglutide it ended after a district court denied a preliminary injunction on April 24, 2025. FDA has since proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need to compound them from bulk substances.

The safety signal is not theoretical. A 2026 pharmacovigilance analysis of the FDA Adverse Event Reporting System examined 81,078 GLP-1 reports from 2018 to 2024, of which 707 involved compounded products. Compared with non-compounded formulations, compounded products showed markedly higher reporting odds ratios for preparation errors (ROR 48.92), contamination (19.00), compounding or manufacturing issues (8.51) and hospitalization (2.35). Disproportionality analysis of a voluntary reporting system establishes association, not causation, and is subject to reporting bias — but the direction and magnitude are hard to dismiss.

We do not use compounded GLP-1s. When a medication is prescribed at u-wellness, it is FDA-approved product.

What good care looks like here

The pattern in this category is the same one we wrote about in IV care: a real clinical intervention sold through a consumer funnel, with the screening quietly removed to make checkout faster.

A serious weight-management program does the opposite. It starts with a full intake — labs, medications, allergies, history, contraindications, goals — screened against clinical data before anything is offered. A physician reviews and finalizes the plan. Titration is paced to the patient rather than the calendar. Protein intake and resistance training are built in, not mentioned in passing. Someone answers the year-three question in year one. And when medication is not the right answer, that is the answer the patient gets.

At u-wellness, weight management begins with a $249 physician consultation. Your intake is screened against licensed clinical data, then read and finalized by a board-certified California physician who owns the prescribing decision. If you do not have recent labs, we run basic lab testing and the physician reads those too. We will not promise a drug before a physician has looked at you.

What happens after the prescription is the part most programs skip. Your AI companion checks in daily and weekly, tracks your weight and how you are tolerating the medication, and builds a personalized nutrition plan and training plan around protecting lean mass. Supplements are available when the physician thinks you need them. A physician supervises the whole arc, not just the first visit.

Weight management is available throughout California. IV care and vitamin shots are Fresno and Clovis.

Fresno leads California in adult obesity. That is exactly why the care offered here should be held to a higher standard than the advertising, not a lower one.

Start with a physician, not a checkout

Weight management at u-wellness begins at u-wellness.com/care/weight-loss. Read more on how it works, pricing, or our care team.

Read more on the model behind this work → AI-Native Care Is Not a Chatbot.

This article is general health information, not medical advice, and does not establish a physician-patient relationship. Semaglutide and tirzepatide are prescription medications with a boxed warning; whether they are appropriate for you is a decision for a licensed clinician who has evaluated you.

References

1. CDC. PLACES: Local Data for Better Health, County Data 2025 release (2023 BRFSS). cdc.gov/places

2. CDC. Nutrition, Physical Activity, and Obesity — Behavioral Risk Factor Surveillance System. Adult obesity prevalence maps

3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183

4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038

5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394

6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725

7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563

8. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2720–2729. doi:10.1111/dom.16275

9. Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss Interventions on Body Composition: A Systematic Review. Ann Intern Med. 2026;179(7):996–1013.

10. Hankosky ER, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes. Diabetes Obes Metab. 2025;27(5):2810–2821.

11. McCall KL, et al. Safety analysis of compounded GLP-1 receptor agonists: a FAERS pharmacovigilance study. Expert Opin Drug Saf. 2026;25(3):581–588.

12. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA statement

13. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List.

14. ZEPBOUND (tirzepatide) injection, full prescribing information. DailyMed

15. WEGOVY (semaglutide) injection, full prescribing information. DailyMed

16. LillyDirect and NovoCare Pharmacy self-pay pricing. Accessed September 8, 2026.